The present study was a randomized, double-blind, placebo-controlled trial in which 40 patients with asthma were enrolled. They were treated with probiotics or placebo: 1 capsule/day for 8 weeks. Pulmonary function test, percentage of CD4+ CD25+ FoxP3+ Tregs, and gene expression of T-bet, GATA-3, RORγt, and Foxp3 in PBMCs were assessed at baseline and after treatment.
Our results showed a significant increase in the expression of FoxP3 and CD4+ CD25+ FoxP3+ Tregs population, while RORγt and GATA3 expression were reduced. In addition, pulmonary function tests showed a significant improvement in forced expiratory volume and forced vital capacity after receiving probiotics.
Our findings demonstrate that 8-week treatment with probiotic supplementation can control T-helper 2-predominant and Th17 pro-inflammatory responses and improve forced vital and forced expiratory volume in asthmatic patients. It seems probiotics can be used besides common treatments for patients with asthma.
方法:本研究是一项随机,双盲,纳入40例哮喘患者的安慰剂对照试验.他们用益生菌或安慰剂治疗:1粒/天,持续8周。肺功能检查,CD4+CD25+FoxP3+Tregs的百分比,和T-bet的基因表达,GATA-3,RORγt,在基线和治疗后评估PBMC中的Foxp3。
结果:我们的结果显示FoxP3和CD4+CD25+FoxP3+Tregs群体的表达显著增加,RORγt和GATA3表达降低。此外,肺功能试验显示,接受益生菌后用力呼气量和用力肺活量显著改善.
结论:我们的研究结果表明,8周的益生菌补充剂治疗可以控制T辅助细胞2型和Th17型促炎反应,并改善哮喘患者的用力肺活量和用力呼气量。似乎益生菌除了用于哮喘患者的常规治疗之外还可以使用。